“…Although the clinical prevalence of hmg1 mutations has not been assessed in a systematic manner, such mutations have been identified in over 150 isolates thus far reported in the literature, many of which are resistant to triazole drugs and lack cyp51A -associated mutations ( 25 – 28 , 35 – 44 ). The most frequent Hmg1 amino acid substitutions associated with triazole drug resistance occur in residues putatively located in the Hmg1 SSD, such as S269, S305, G307, and I412, with several studies showing that some of these mutations, namely, F262del, S305P, I412S, S269F, and E306K, impart decreased susceptibility to multiple triazoles when genetically introduced into a susceptible laboratory strain ( 25 , 26 , 36 , 40 ). The mechanism by which hmg1 mutations alter triazole resistance remains to be defined; however, it is speculated that amino acid substitutions in the SSD impair its ability to sense sterols and signal for Hmg1 degradation ( 25 , 26 , 28 ).…”